AR073848A1 - USE OF THE 4- (3- (HEXAHYDROCICLOPENTA (C) PIRROL-2 (1H) -IL) PROPOXI) BENZAMIDE FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF SOIL DISORDERS. PHARMACEUTICAL COMPOSITION - Google Patents
USE OF THE 4- (3- (HEXAHYDROCICLOPENTA (C) PIRROL-2 (1H) -IL) PROPOXI) BENZAMIDE FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF SOIL DISORDERS. PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR073848A1 AR073848A1 ARP090103933A ARP090103933A AR073848A1 AR 073848 A1 AR073848 A1 AR 073848A1 AR P090103933 A ARP090103933 A AR P090103933A AR P090103933 A ARP090103933 A AR P090103933A AR 073848 A1 AR073848 A1 AR 073848A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzamide
- treatment
- propoxy
- disorders
- hexahydrociclopenta
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000002689 soil Substances 0.000 title 1
- 208000019116 sleep disease Diseases 0.000 abstract 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 2
- MRNMYWNBLVJWKG-UHFFFAOYSA-N 4-[3-(3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl)propoxy]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OCCCN1CC2CCCC2C1 MRNMYWNBLVJWKG-UHFFFAOYSA-N 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010041349 Somnolence Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 150000003891 oxalate salts Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilizacion de la 4-{3-[hexadihidrociclopenta[c]pirrol-2-(1H)-il]propoxi}benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos el sueno. Reivindicacion 5: Composiciones farmacéuticas que contienen 4-{3-[hexadihidrociclopenta[c]pirrol-2-(1H)-il]propoxi}benzamida, o una de sus sales de adicion a un ácido o a una base farmacéuticamente aceptable, en combinacion con uno o varios excipientes farmacéuticamente aceptables, utiles para el tratamiento de los trastornos del sueno que son la narcolepsia, las hipersomnias que aparecen durante el síndrome de apnea obstructiva del sueno o el síndrome de hiperactividad con déficits atencionales y las somnolencias diurnas, así como el tratamiento de los trastornos del sueno asociados al envejecimiento cerebral, a las enfermedades neurodegenerativas o a los traumatismos craneales. Reivindicacion 8: Composiciones farmacéuticas segun una de las reivindicaciones 5 a 7 caracterizadas porque la 4-{3-[hexahidrociclopenta[c]pirrol-2-(1H)-il]propoxi}benzamida está presente en la forma de un oxalato o de un hidrocloruro.Use of 4- {3- [hexadihydrocyclopenta [c] pyrrole-2- (1H) -yl] propoxy} benzamide to obtain medicines for the treatment of sleep disorders. Claim 5: Pharmaceutical compositions containing 4- {3- [hexadihydrocyclopenta [c] pyrrol-2- (1H) -yl] propoxy} benzamide, or a pharmaceutically acceptable acid or base addition salt thereof, in combination with one or more pharmaceutically acceptable excipients, useful for the treatment of sleep disorders that are narcolepsy, hypersomnias that appear during obstructive sleep apnea syndrome or hyperactivity syndrome with attention deficits and daytime sleepiness, as well as treatment of sleep disorders associated with brain aging, neurodegenerative diseases or head injuries. Claim 8: Pharmaceutical compositions according to one of claims 5 to 7, characterized in that 4- {3- [hexahydrocyclopenta [c] pyrrol-2- (1H) -yl] propoxy} benzamide is present in the form of an oxalate or a hydrochloride
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0805721A FR2937251B1 (en) | 2008-10-16 | 2008-10-16 | USE OF 4- {3- HEXAHYDROCYCLOPENTA} C! PYRROL-2 (1H) -YL! PROPOXY} BENZAMIDE FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF SLEEP DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073848A1 true AR073848A1 (en) | 2010-12-09 |
Family
ID=40416951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103933A AR073848A1 (en) | 2008-10-16 | 2009-10-14 | USE OF THE 4- (3- (HEXAHYDROCICLOPENTA (C) PIRROL-2 (1H) -IL) PROPOXI) BENZAMIDE FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF SOIL DISORDERS. PHARMACEUTICAL COMPOSITION |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR073848A1 (en) |
| FR (1) | FR2937251B1 (en) |
| WO (1) | WO2010043787A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2974729B1 (en) * | 2011-05-02 | 2013-04-19 | Servier Lab | NOVEL ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE AND AN ACETYLCHOLINESTERASE INHIBITOR AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR2976285B1 (en) * | 2011-06-08 | 2013-05-24 | Servier Lab | PROCESS FOR THE SYNTHESIS AND CRYSTALLINE FORM OF 4- {3- [CIS-HEXAHYDROCYPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE HYDROCHLORIDE AS WELL AS THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR2976286B1 (en) * | 2011-06-08 | 2013-05-24 | Servier Lab | 4- {3- [TRANS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR2983732B1 (en) * | 2011-12-09 | 2013-11-22 | Servier Lab | NOVEL ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} PHARMACEUTICALS CONTAINING THE SAME |
| FR2999179A1 (en) * | 2012-12-07 | 2014-06-13 | Servier Lab | PROCESS FOR THE SYNTHESIS OF A SALT FOR ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID OF 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE, AND ASSOCIATED CRYSTALLINE FORMS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866647B1 (en) * | 2004-02-20 | 2006-10-27 | Servier Lab | NOVEL AZABICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
2008
- 2008-10-16 FR FR0805721A patent/FR2937251B1/en not_active Expired - Fee Related
-
2009
- 2009-10-14 AR ARP090103933A patent/AR073848A1/en unknown
- 2009-10-15 WO PCT/FR2009/001208 patent/WO2010043787A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR2937251B1 (en) | 2011-03-18 |
| WO2010043787A1 (en) | 2010-04-22 |
| FR2937251A1 (en) | 2010-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398836B2 (en) | Application of R-ketamine and its salts as pharmaceuticals | |
| AR085219A1 (en) | 6-CICLOALQUIL-PIRAZOLOPIRIMIDINONAS FOR THE TREATMENT OF CNS DISORDERS | |
| EA201290519A1 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE QUINOLIN AMIDA M1 RECEPTOR | |
| CO6531470A2 (en) | SUBSTITUTED BENZAMIDA DERIVATIVES | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR OF TETRAHYDROQUINOLINE AMIDE | |
| UY26863A1 (en) | PIPERAZINE DERIVATIVES | |
| AR073848A1 (en) | USE OF THE 4- (3- (HEXAHYDROCICLOPENTA (C) PIRROL-2 (1H) -IL) PROPOXI) BENZAMIDE FOR THE OBTAINING OF DRUGS INTENDED FOR THE TREATMENT OF SOIL DISORDERS. PHARMACEUTICAL COMPOSITION | |
| BR112015018168A2 (en) | soft rock inhibitors | |
| JP2012504560A5 (en) | ||
| MX2013008056A (en) | 1,4-oxazepines as bace1 and/or bace2 inhibitors. | |
| JP2019518732A5 (en) | ||
| JP2020503246A5 (en) | ||
| MX2020005735A (en) | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES. | |
| UA101393C2 (en) | COMPOSITIONS AND USE OF TRIAZOLE DERIVATIVES FOR TREATING β-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
| CY1114400T1 (en) | THERAPEUTIC APPLICATIONS OF KINAZOLINEDIONI PRODUCERS | |
| RU2018134262A (en) | 5-Ethyl-4-methyl-pyrazole-3-carboxamide derivative with TAAR agonist activity | |
| UY27204A1 (en) | PIERACINE DERIVATIVES | |
| JP2015521642A5 (en) | ||
| CO7200248A2 (en) | Ethinyl derivatives as modulators of mglur5 receptor activity | |
| JP2019513755A5 (en) | ||
| DOP2009000209A (en) | ADDITION SALTS OF ACID, HYDRATES AND POLYMORPHES OF ETHYL-AMIDA ACID 5- (2,4-DIHIDROXI-5-ISOPROPILFENIL) -4- (4-MORFOLIN-4-IL-METHYL-PHENYL) -ISOXAZOL-3- CARBOXYLIC, AND FORMULATIONS THAT UNDERSTAND THESE FORMS | |
| EA200801488A1 (en) | SUBSTITUTED PHENETHYLAMINES OWNING SEROTONINERGIC AND / OR NOREPINEFININERGIC ACTIVITY | |
| IL206615A0 (en) | Piperidine sulfonamide derivatives | |
| ATE506941T1 (en) | TREATMENT OF PSYCHIATRIC PATIENTS WITH SLEEP DISORDERS AND/OR EXCESSIVE DAYTIME SLEEPING WITH PALIPERIDONE | |
| ES2363252T3 (en) | USE OF AGOMELATINE FOR THE OBTAINING OF MEDICINES FOR THE TREATMENT OF SMITH MEGENIS SYNDROME. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |